Literature DB >> 11067933

Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.

E J Ryan1, E McNeela, M Pizza, R Rappuoli, L O'Neill, K H Mills.   

Abstract

We have examined the roles of enzyme activity and the nontoxic AB complex of heat-labile toxin (LT) from Escherichia coli on its adjuvant and immunomodulatory properties. LTK63, an LT mutant that is completely devoid of enzyme activity, enhanced Th1 responses to coinjected Ags at low adjuvant dose. In contrast, LTR72, a partially detoxified mutant, enhanced Th2 responses and when administered intranasally to mice before infection with Bordetella pertussis suppressed Th1 responses and delayed bacterial clearance from the lungs. LTR72 or wild-type LT inhibited Ag-induced IFN-gamma production by Th1 cells, and LT enhanced IL-5 production by Th2 cells in vitro. Each of the toxins enhanced B7-1 expression on macrophages, but enhancement of B7-2 expression was dependent on enzyme activity. We also observed distinct effects of the nontoxic AB complex and enzyme activity on inflammatory cytokine production. LT and LTR72 suppressed LPS and IFN-gamma induced TNF-alpha and IL-12 production, but enhanced IL-10 secretion by macrophages in vitro and suppressed IL-12 production in vivo in a murine model of LPS-induced shock. In contrast, LTK63 augmented the production of IL-12 and TNF-alpha. Furthermore, LTK63 enhanced NF-kappaB translocation, whereas low doses of LTR72 or LT failed to activate NF-kappaB, but stimulated cAMP production. Thus, E. coli LT appears to be capable of suppressing Th1 responses and enhancing Th2 responses through the modulatory effects of enzyme activity on NF-kappaB activation and IL-12 production. In contrast, the nontoxic AB complex can stimulate acquired immune responses by activating components of the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11067933     DOI: 10.4049/jimmunol.165.10.5750

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.

Authors:  Pádraig J Ross; Ed C Lavelle; Kingston H G Mills; Aoife P Boyd
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 2.  Th17 cytokines and vaccine-induced immunity.

Authors:  Yinyao Lin; Samantha R Slight; Shabaana A Khader
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

Review 3.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

4.  Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines.

Authors:  Oretta Finco; Elisabetta Frigimelica; Francesca Buricchi; Roberto Petracca; Giuliano Galli; Elisa Faenzi; Eva Meoni; Alessandra Bonci; Mauro Agnusdei; Filomena Nardelli; Erika Bartolini; Maria Scarselli; Elena Caproni; Donatello Laera; Luisanna Zedda; David Skibinski; Serena Giovinazzi; Riccardo Bastone; Elvira Ianni; Roberto Cevenini; Guido Grandi; Renata Grifantini
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

Review 5.  Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.

Authors:  Shuang Liang; George Hajishengallis
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

6.  Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.

Authors:  Kenneth C Bagley; George K Lewis; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

7.  CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans.

Authors:  Eva Meoni; Elisa Faenzi; Elisabetta Frigimelica; Luisanna Zedda; David Skibinski; Serena Giovinazzi; Alessandra Bonci; Roberto Petracca; Erika Bartolini; Giuliano Galli; Mauro Agnusdei; Filomena Nardelli; Francesca Buricchi; Nathalie Norais; Ilaria Ferlenghi; Manuela Donati; Roberto Cevenini; Oretta Finco; Guido Grandi; Renata Grifantini
Journal:  Infect Immun       Date:  2009-07-13       Impact factor: 3.441

8.  Identification and characterization of intestinal antigen-presenting cells involved in uptake and processing of a nontoxic recombinant chimeric mucosal immunogen based on cholera toxin using imaging flow cytometry.

Authors:  Weiwei Zhao; Hans Minderman; Michael W Russell
Journal:  Clin Vaccine Immunol       Date:  2013-11-06

9.  Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.

Authors:  Frances Bowe; Ed C Lavelle; Edel A McNeela; Christine Hale; Simon Clare; Beatrice Arico; Marzia M Giuliani; Aaron Rae; Alan Huett; Rino Rappuoli; Gordon Dougan; Kingston H G Mills
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 10.  Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

Authors:  George Hajishengallis; Terry D Connell
Journal:  Vet Immunol Immunopathol       Date:  2012-09-26       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.